An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses

Journal of General Virology

Volumn 91, Issue 6, 2010, Pages 1407-1417

  Lobigs, Mario ^a   Pavy, Megan ^a   Hall, Roy A ^b   Lobigs, Päivi ^a   Cooper, Peter ^a,c   Komiya, Tomoyoshi ^d   Toriniwa, Hiroko ^d   Petrovsky, Nikolai ^c,e  

^a Biology and Environment   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c VAXINE PTY LTD   (Australia)

^d KITASATO INSTITUTE   (Japan)

^e FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ADVAX; ALUMINUM SALT; CELL CULTURE GROWN INACTIVATED JAPANESE ENCEPHALITIS VACCINE; CHIMERIVAX; INACTIVATED VIRUS VACCINE; INULIN; JAPANESE ENCEPHALITIS VACCINE; JESPECT; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CELL CULTURE; CELL GROWTH; CONTROLLED STUDY; CROSS PROTECTION; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; FEMALE; FLAVIVIRUS; HELPER CELL; HORSE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOPOTENTIATION; JAPAN; JAPANESE ENCEPHALITIS; JAPANESE ENCEPHALITIS VIRUS; LOW DRUG DOSE; MOUSE; MURRAY VALLEY ENCEPHALITIS VIRUS; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TH2 CELL; VACCINE PRODUCTION; VERO CELL; VIRUS IMMUNITY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; CROSS REACTIONS; ENCEPHALITIS, JAPANESE; FEMALE; FLAVIVIRUS; HORSES; JAPANESE ENCEPHALITIS VACCINES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; SURVIVAL ANALYSIS; TH1 CELLS; TH2 CELLS; VACCINATION; VACCINES, INACTIVATED; VERO CELLS;

ANIMALIA; EQUIDAE; JAPANESE ENCEPHALITIS VIRUS; MURRAY VALLEY ENCEPHALITIS VIRUS; MUS; RODENTIA;

EID: 77952717965     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.019190-0     Document Type: Article

References (54)

1. Appaiahgari, M. B. & Vrati, S. (2004). Immunogenicity and protective efficacy in mice of a formaldehyde-inactivated Indian strain of Japanese encephalitis virus grown in Vero cells. Vaccine 22, 3669-3675.
2. Barrett, A. D. & Gould, E. A. (1986). Comparison of neurovirulence of different strains of yellow fever virus in mice. J Gen Virol 67, 631-637. (Pubitemid 16048042)
3. Beasley, D. W., Lewthwaite, P. & Solomon, T. (2008). Current use and development of vaccines for Japanese encephalitis. Expert Opin Biol Ther 8, 95-106. (Pubitemid 351233725)
4. Broom, A. K., Wallace, M. J., Mackenzie, J. S., Smith, D. W. & Hall, R. A. (2000). Immunization with gamma globulin of Murray Valley encephalitis virus and with an inactivated Japanese encephalitis virus vaccine as prophylaxis against Australian encephalitis: evaluation in a mouse model. J Med Virol 61, 259-265.
5. Chu, J. H., Chiang, C. C. & Ng, M. L. (2007). Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection. J Immunol 178, 2699-2705.
6. Colombage, G., Hall, R., Pavy, M. & Lobigs, M. (1998). DNA-based and alphavirus-vectored immunisation with prM and E proteins elicits long-lived and protective immunity against the flavivirus, Murray Valley encephalitis virus. Virology 250, 151-163. (Pubitemid 28471771)
7. Coutelier, J. P., van der Logt, J. T., Heessen, F. W., Warnier, G. & Van Snick, J. (1987). IgG2a restriction of murine antibodies elicited by viral infections. J Exp Med 165, 64-69.
8. Ferguson, M., Kurane, I., Wimalaratne, O., Shin, J. & Wood, D. (2007). WHO informal consultation on the scientific basis of specifications for production and control of inactivated Japanese encephalitis vaccines for human use, Geneva, Switzerland, 1-2 June 2006. Vaccine 25, 5233-5243. (Pubitemid 46977544)
9. 50 assays for Japanese encephalitis virus (JE) antibodies. Biologicals 36, 111-116.
10. Fischer, M., Casey, C. & Chen, R. T. (2007). Promise of new Japanese encephalitis vaccines. Lancet 370, 1806-1808. (Pubitemid 350186051)
11. Goverdhan, M. K., Kulkarni, A. B., Gupta, A. K., Tupe, C. D. & Rodrigues, J. J. (1992). Two-way cross-protection between West Nile and Japanese encephalitis viruses in bonnet macaques. Acta Virol 36, 277-283.
12. Gupta, R. K. (1998). Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev 32, 155-172.
13. Halstead, S. B. (2003). Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 60, 421-467.
14. Halstead, S. B. & Tsai, T. F. (2004). Japanese encephalitis vaccines. In Vaccines, 4th edn, pp. 919-958. Edited by S. A. Plotkin & W. A. Orenstein. Philadelphia: Saunders.
15. Hammon, W. M. & Sather, G. E. (1956). Immunity of hamsters to West Nile and Murray Valley viruses following immunization with St Louis and Japanese B. Proc Soc Exp Biol Med 91, 521-524.
16. Hawkes, R. A. (1964). Enhancement of the infectivity of arboviruses by specific antisera produced in domestic fowls. Aust J Exp Biol Med Sci 42, 465-482.
17. Hoke, C. H., Nisalak, A., Sangawhipa, N., Jatanasen, S., Laorakapongse, T., Innis, B. L., Kotchasenee, S., Gingrich, J. B., Latendresse, J. & other authors (1988). Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med 319, 608-614.
18. Hombach, J., Solomon, T., Kurane, I., Jacobson, J. & Wood, D. (2005). Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine 23, 5205-5211. (Pubitemid 41443426)
19. Huber, V. C., McKeon, R. M., Brackin, M. N., Miller, L. A., Keating, R., Brown, S. A., Makarova, N., Perez, D. R., Macdonald, G. H. & other authors (2006). Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin Vaccine Immunol 13, 981-990.
20. Huisman, W., Martina, B. E., Rimmelzwaan, G. F., Gruters, R. A. & Osterhaus, A. D. (2009). Vaccine-induced enhancement of viral infections. Vaccine 27, 505-512.
21. Kanesa-Thasan, N., Putnak, J. R., Mangiafico, J. A., Saluzzo, J. E. & Ludwig, G. V. (2002). Short report: absence of protective neutralizing antibodies to West Nile virus in subjects following vaccination with Japanese encephalitis or dengue vaccines. Am J Trop Med Hyg 66, 115-116.
22. Konishi, E. & Suzuki, T. (2002). Ratios of subclinical to clinical Japanese encephalitis (JE) virus infections in vaccinated populations: evaluation of an inactivated JE vaccine by comparing the ratios with those in unvaccinated populations. Vaccine 21, 98-107. (Pubitemid 35351355)
23. Kuzuhara, S., Nakamura, H., Hayashida, K., Obata, J., Abe, M., Sonoda, K., Nishiyama, K., Sugawara, K., Takeda, K. & other authors (2003). Non-clinical and phase I clinical trials of a Vero cell-derived inactivated Japanese encephalitis vaccine. Vaccine 21, 4519-4526.
24. Licon Luna, R. M., Lee, E., Müllbacher, A., Blanden, R. V., Langman, R. & Lobigs, M. (2002). Lack of both Fas ligand and perforin protects from flavivirus-mediated encephalitis in mice. J Virol 76, 3202-3211. (Pubitemid 34224521)
25. Lobigs, M., Pavy, M. & Hall, R. A. (2003). Cross-protective and infection-enhancing immunity in mice vaccinated against flaviviruses belonging to the Japanese encephalitis virus serocomplex. Vaccine 21, 1572-1579. (Pubitemid 36287591)
26. Lobigs, M., Larena, M., Alsharifi, M., Lee, E. & Pavy, M. (2009). Live chimeric and inactivated Japanese encephalitis virus vaccines differ in their cross-protective values against Murray Valley encephalitis virus. J Virol 83, 2436-2445.
27. Mackenzie, J. S., Gubler, D. J. & Petersen, L. R. (2004). Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med 10, S98-S109.
28. Markine-Goriaynoff, D. & Coutelier, J. P. (2002). Increased efficacy of the immunoglobulin G2a subclass in antibody-mediated protection against lactate dehydrogenase-elevating virus-induced polioencephalomyelitis revealed with switch mutants. J Virol 76, 432-435. (Pubitemid 33139030)
29. Martin, R. M., Brady, J. L. & Lew, A. M. (1998). The need for IgG2c specific antiserum when isotyping antibodies from C57BL/6 and NOD mice. J Immunol Methods 212, 187-192.
30. Martina, B. E., Koraka, P., van den Doel, P., van Amerongen, G., Rimmelzwaan, G. F. & Osterhaus, A. D. (2008). Immunization with West Nile virus envelope domain III protects mice against lethal infection with homologous and heterologous virus. Vaccine 26, 153-157. (Pubitemid 50008834)
31. McKee, A. S., Munks, M. W. & Marrack, P. (2007). How do adjuvants work? Important considerations for new generation adjuvants. Immunity 27, 687-690.
32. Moghaddam, A., Olszewska, W., Wang, B., Tregoning, J. S., Helson, R., Sattentau, Q. J. & Openshaw, P. J. (2006). A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat Med 12, 905-907. (Pubitemid 44175141)
33. Monath, T. P. (2002a). Japanese encephalitis vaccines: current vaccines and future prospects. Curr Top Microbiol Immunol 267, 105-138. (Pubitemid 34411361)
34. Monath, T. P. (2002b). Editorial: Jennerian vaccination against West Nile virus. Am J Trop Med Hyg 66, 113-114.
35. Monath, T. P., Guirakhoo, F., Nichols, R., Yoksan, S., Schrader, R., Murphy, C., Blum, P., Woodward, S., McCarthy, K. & other authors (2003). Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis 188, 1213-1230.
36. Mullbacher, A., Lobigs, M. & Lee, E. (2003). Immunobiology of mosquito-borne encephalitic flaviviruses. Adv Virus Res 60, 87-120.
37. Nimmerjahn, F. & Ravetch, J. V. (2005). Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science 310, 1510-1512.
38. Petrovsky, N. (2006). Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity. Vaccine 24 (Suppl. 2), 26-29.
39. Petrovsky, N. (2008). Freeing vaccine adjuvants from dangerous immunological dogma. Expert Rev Vaccines 7, 7-10.
40. Polack, F. P. (2007). Atypical measles and enhanced respiratory syncytial virus disease (ERD) made simple. Pediatr Res 62, 111-115.
41. Poland, J. D., Cropp, C. B., Craven, R. B. & Monath, T. P. (1990). Evaluation of the potency and safety of inactivated Japanese encephalitis vaccine in US inhabitants. J Infect Dis 161, 878-882.
42. Ranasinghe, C. & Ramshaw, I. A. (2009). Genetic heterologous prime-boost vaccination strategies for improved systemic and mucosal immunity. Expert Rev Vaccines 8, 1171-1181.
43. Silva, D. G., Cooper, P. D. & Petrovsky, N. (2004). Inulin-derived adjuvants efficiently promote both Th1 and Th2 immune responses. Immunol Cell Biol 82, 611-616.
44. Solomon, T. (2004). Flavivirus encephalitis. N Engl J Med 351, 370-378.
45. Srivastava, A. K., Putnak, J. R., Lee, S. H., Hong, S. P., Moon, S. B., Barvir, D. A., Zhao, B., Olson, R. A., Kim, S. O. & other authors (2001). A purified inactivated Japanese encephalitis virus vaccine made in Vero cells. Vaccine 19, 4557-4565. (Pubitemid 32718682)
46. Sugawara, K., Nishiyama, K., Ishikawa, Y., Abe, M., Sonoda, K., Komatsu, K., Horikawa, Y., Takeda, K., Honda, T. & other authors (2002). Development of Vero cell-derived inactivated Japanese encephalitis vaccine. Biologicals 30, 303-314. (Pubitemid 36268966)
47. Takasaki, T., Yabe, S., Nerome, R., Ito, M., Yamada, K. & Kurane, I. (2003). Partial protective effect of inactivated Japanese encephalitis vaccine on lethal West Nile virus infection in mice. Vaccine 21, 4514-4518. (Pubitemid 37315770)
48. Tang, F., Zhang, J. S., Liu,W., Zhao, Q.M., Zhang, F.,Wu, X.M., Yang, H., Ly, H. & Cao, W. C. (2008). Failure of Japanese encephalitis vaccine and infection in inducing neutralizing antibodies against West Nile virus, People's Republic of China. Am J Trop Med Hyg 78, 999-1001. (Pubitemid 351967822)
49. Tauber, E., Kollaritsch, H., Korinek, M., Rendi-Wagner, P., Jilma, B., Firbas, C., Schranz, S., Jong, E., Klingler, A. & other authors (2007). Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet 370, 1847-1853. (Pubitemid 350186053)
50. Toriniwa, H. & Komiya, T. (2008). Long-term stability of Vero cell-derived inactivated Japanese encephalitis vaccine prepared using serum-free medium. Vaccine 26, 3680-3689.
51. Tsai, T. F., Popovici, F., Cernescu, C., Campbell, G. L. & Nedelcu, N. I. (1998). West Nile encephalitis epidemic in southeastern Romania. Lancet 352, 767-771. (Pubitemid 28404558)
52. Wallace, M. J., Smith, D. W., Broom, A. K., Mackenzie, J. S., Hall, R. A., Shellam, G. R. & McMinn, P. C. (2003). Antibody-dependent enhancement of Murray Valley encephalitis virus virulence in mice. J Gen Virol 84, 1723-1728.
53. Williams, D. T., Daniels, P. W., Lunt, R. A., Wang, L. F., Newberry, K. M. & Mackenzie, J. S. (2001). Experimental infections of pigs with Japanese encephalitis virus and closely related Australian flaviviruses. Am J Trop Med Hyg 65, 379-387.
54. Yang, K. D., Yeh, W. T., Yang, M. Y., Chen, R. F. & Shaio, M. F. (2001). Antibody-dependent enhancement of heterotypic dengue infections involved in suppression of IFNγ production. J Med Virol 63, 150-157.